Bind proposes IPO
Bind Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $80.5 million in an IPO underwritten by Credit Suisse; Cowen; Stifel; and JMP Securities. Bind is developing Accurins, which are selective and programmable nanoparticle-encapsulated therapeutics designed to accumulate at the site of disease.
The company's lead internal program is BIND-014, which is in Phase II testing as second-line treatment for non-small cell lung cancer (NSCLC) and first-line treatment for metastatic castration-resistant prostate cancer (CRPC), with data expected in 2H14. The compound is a polymeric nanoparticle containing docetaxel targets prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) and concentrates in the neovasculature surrounding tumors. ...